Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Stanford University
Stanford University
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
H. Lee Moffitt Cancer Center and Research Institute
University Health Network, Toronto
University of California, Irvine
Valo Therapeutics Oy
Qingdao Sino-Cell Biomedicine Co., Ltd.
Memorial Sloan Kettering Cancer Center
Centre Hospitalier Universitaire Vaudois
Immatics US, Inc.
Acepodia Biotech, Inc.
Adaptimmune
BioEclipse Therapeutics
Gilead Sciences
Fate Therapeutics
Fate Therapeutics
Fate Therapeutics
H. Lee Moffitt Cancer Center and Research Institute
Fate Therapeutics
BGI, China
Genocea Biosciences, Inc.
GlaxoSmithKline
MaxCyte, Inc.
Sichuan University
Aduro Biotech, Inc.
Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Guangzhou Institute of Respiratory Disease
Mayo Clinic
Merck KGaA, Darmstadt, Germany
Shenzhen Second People's Hospital
Hoosier Cancer Research Network
Northwestern University
University of Washington
Cancer Research UK
Roswell Park Cancer Institute